◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksL › LMRI

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-17

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) operates in the MEDICAL DEVICES industry and is headquartered in Raleigh, United States with about 5,000 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, LMRI reported $1.0B in revenue and ($47M) in net income.

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States.

Interactive charts & full statements → Open the LMRI valuation workbench →

LMRI Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-31
Total Revenue$1.0B$1.0B$949M$936M
Gross Profit$123M$117M$96M$99M
Gross Margin %11.8%11.5%10.2%10.6%
Operating Income (EBIT)$14M$27M$55M$22M
Operating Margin %1.4%2.6%5.8%2.4%
Net Income($28M)($47M)($94M)($122M)
Net Margin %-2.7%-4.6%-9.9%-13.1%
EBITDA$111M$142M$114M$95M
Earnings Per Share (EPS)$-0.38$-0.66$-1.00$-1.29
Shares Outstanding (M)96M71M95M95M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LMRI Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$264M$253M$268M$259M$251M$245M$248M
Gross Profit$29M$25M$30M$40M$39M$37M$22M
Gross Margin %10.9%9.8%11.1%15.3%15.6%14.9%8.7%
Operating Income (EBIT)$4M$5M($7M)$13M$11M$10M$15M
Operating Margin %1.7%1.8%-2.8%5.0%4.4%4.1%6.2%
Net Income$3M$2M($29M)($4M)($7M)($8M)($25M)
Net Margin %1.0%0.7%-10.7%-1.4%-2.9%-3.1%-10.1%
EBITDA$19M$33M$15M$44M$38M$29M
Earnings Per Share (EPS)$0.03$0.02$-0.38$-0.04$-0.08$-0.26
Shares Outstanding (M)96M96M75M83M95M95M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LMRI Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-31
Cash from Operations (CFO)$65M$17M$41M$38M
Capital Expenditures (CapEx)$33M$23M$28M$24M
Free Cash Flow (FCF)$32M($6M)$13M$14M
FCF Margin %3.0%-0.6%1.4%1.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LMRI Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Cash from Operations (CFO)$33M$3M$17M$12M$2M($14M)$25M
Capital Expenditures (CapEx)$10M$5M$4M$14M$5M$1M$6M
Free Cash Flow (FCF)$23M($2M)$13M($2M)($3M)($15M)$19M
FCF Margin %8.8%-0.9%4.8%-0.7%-1.0%-6.1%7.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LMRI Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-31
Total Assets$1.8B$1.8B$1.7B$1.7B
Cash & Cash Equivalents$70M$59M$26M$20M
Total Liabilities$1.2B$1.2B$1.5B$1.5B
Total Debt (Short + Long-Term)$862M$858M$1.2B$1.2B
Total Shareholders' Equity$615M$586M$162M$198M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LMRI viewer.

Other Companies in MEDICAL DEVICES

← LMPAll “L” companiesLMT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.